492 related articles for article (PubMed ID: 28012875)
1. Advances in understanding and management of retinopathy of prematurity.
Hartnett ME
Surv Ophthalmol; 2017; 62(3):257-276. PubMed ID: 28012875
[TBL] [Abstract][Full Text] [Related]
2. Retinopathy of prematurity.
Jordan CO
Pediatr Clin North Am; 2014 Jun; 61(3):567-77. PubMed ID: 24852153
[TBL] [Abstract][Full Text] [Related]
3. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
[TBL] [Abstract][Full Text] [Related]
4. Systemic Solutions in Retinopathy of Prematurity.
Moshfeghi DM
Am J Ophthalmol; 2018 Sep; 193():xiv-xviii. PubMed ID: 29792838
[TBL] [Abstract][Full Text] [Related]
5. Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor.
Hartnett ME
Am J Ophthalmol; 2020 Oct; 218():208-213. PubMed ID: 32450064
[TBL] [Abstract][Full Text] [Related]
6. Five years of treatment for retinopathy of prematurity in Sweden: results from SWEDROP, a national quality register.
Holmström G; Hellström A; Jakobsson P; Lundgren P; Tornqvist K; Wallin A
Br J Ophthalmol; 2016 Dec; 100(12):1656-1661. PubMed ID: 26969711
[TBL] [Abstract][Full Text] [Related]
7. [Retinopathy of prematurity - therapy. Part 2].
Prepiaková Z; Tomčíková D; Kostolná B; Gerinec A
Cesk Slov Oftalmol; 2014 Apr; 70(2):50-4. PubMed ID: 25030312
[TBL] [Abstract][Full Text] [Related]
8. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
[TBL] [Abstract][Full Text] [Related]
9. Increase in treatment of retinopathy of prematurity in the Netherlands from 2010 to 2017.
Trzcionkowska K; Vehmeijer WBHJ; Kerkhoff FT; Bauer NJC; Bennebroek CAM; Dijk PH; Dijkman KP; van den Dungen FAM; Eggink CA; Feenstra RPG; Groenendaal F; van Heijst AF; van der Hoeven MAHBM; Kornelisse RF; Kraal-Biezen E; Lopriore E; Onland W; Renardel de Lavalette VW; van Rijn LJ; Schuerman FABA; Simonsz HJ; Voskuil-Kerkhof ESM; Witlox RSGM; Termote JUM; Schalij-Delfos NE
Acta Ophthalmol; 2021 Feb; 99(1):97-103. PubMed ID: 32701185
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.
Hartnett ME
Clin Perinatol; 2014 Dec; 41(4):925-43. PubMed ID: 25459781
[TBL] [Abstract][Full Text] [Related]
11. Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study.
Lyu J; Zhang Q; Chen C; Xu Y; Ji X; Zhao P
BMC Ophthalmol; 2019 Feb; 19(1):60. PubMed ID: 30808338
[TBL] [Abstract][Full Text] [Related]
12. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
Kang HG; Kim TY; Han J; Han SH
Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
[TBL] [Abstract][Full Text] [Related]
14. Treatment of retinopathy of prematurity (ROP) outside International Classification of ROP (ICROP) guidelines.
Rajan RP; Kohli P; Babu N; Dakshayini C; Tandon M; Ramasamy K
Graefes Arch Clin Exp Ophthalmol; 2020 Jun; 258(6):1205-1210. PubMed ID: 32322963
[TBL] [Abstract][Full Text] [Related]
15. The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity.
Akdogan M; Cevik SG; Sahin O
Indian J Ophthalmol; 2019 Jun; 67(6):879-883. PubMed ID: 31124508
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.
Nazari H; Modarres M; Parvaresh MM; Ghasemi Falavarjani K
Graefes Arch Clin Exp Ophthalmol; 2010 Dec; 248(12):1713-8. PubMed ID: 20582706
[TBL] [Abstract][Full Text] [Related]
17. Successful Surgical Management of Retinopathy of Prematurity Showing Rapid Progression despite Extensive Retinal Photocoagulation.
Gadkari SS; Kulkarni SR; Kamdar RR; Deshpande M
Middle East Afr J Ophthalmol; 2015; 22(3):393-5. PubMed ID: 26180484
[TBL] [Abstract][Full Text] [Related]
18. [Laser treatment or intravitreal VEGF inhibition for aggressive posterior retinopathy of prematurity?].
Barth T; Hufendiek K; Helbig H; Oberacher-Velten I
Ophthalmologe; 2015 Jun; 112(6):520-4. PubMed ID: 25573085
[TBL] [Abstract][Full Text] [Related]
19. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
Tan QQ; Christiansen SP; Wang J
PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
[TBL] [Abstract][Full Text] [Related]
20. Zone I retinopathy of prematurity.
Katz X; Kychenthal A; Dorta P
J AAPOS; 2000 Dec; 4(6):373-6. PubMed ID: 11124674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
